EC updates guidance on devices with animal tissues
This article was originally published in Clinica
The European Commission has published a final draft of a revised guidance document (meddev) on devices utilising tissues or derivatives originating from animals for which a TSE risk is suspected. The purpose of the guidance is to aid the common application of Commission Directive 2003/32/EC on devices containing animal tissues by clarifying some aspects of its interpretation. In particular, it addresses the evaluation performed by the notified body, the activities of the co-ordinating competent authority and the verification role of the other competent authorities. Meddev 2.11/1 revision 2 is dated January 2008, and is available at: http://ec.europa.eu/enterprise/ medical-devices/meddev/2-11-1-rev2-bsetse-january2008.pdf
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.